ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 147,60
1,20%
Dow Jones
43 621,16
0,37%
DAX
22 723,28
1,46%
Brent Oil
72,45
-0,19%
Bitcoin
88 381,59
-0,28%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Redhill Biopharma Ltd (RDHL)

  7. Redhill Biopharma Ltd (RDHL) Actualités

RDHL

Redhill Biopharma (RDHL)

Redhill Biopharma Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RDHL
DateHeureSourceTitreSymboleSociété
25/02/202513h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
25/02/202513h00PR Newswire (US)RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus RoyaltiesNASDAQ:RDHLRedhill Biopharma Ltd
04/02/202513h00PR Newswire (US)RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate CancerNASDAQ:RDHLRedhill Biopharma Ltd
03/02/202522h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RDHLRedhill Biopharma Ltd
21/01/202513h00PR Newswire (US)RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing PublishedNASDAQ:RDHLRedhill Biopharma Ltd
10/12/202413h00PR Newswire (US)Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentNASDAQ:RDHLRedhill Biopharma Ltd
02/12/202413h00PR Newswire (US)RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme CourtNASDAQ:RDHLRedhill Biopharma Ltd
14/11/202418h22Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RDHLRedhill Biopharma Ltd
28/10/202412h00PR Newswire (US)RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDNASDAQ:RDHLRedhill Biopharma Ltd
22/10/202413h00PR Newswire (US)RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryNASDAQ:RDHLRedhill Biopharma Ltd
14/10/202413h00PR Newswire (US)RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentNASDAQ:RDHLRedhill Biopharma Ltd
01/10/202413h00PR Newswire (US)RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million CaliforniansNASDAQ:RDHLRedhill Biopharma Ltd
30/09/202413h00PR Newswire (US)RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041NASDAQ:RDHLRedhill Biopharma Ltd
09/09/202413h00PR Newswire (US)RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology GuidelinesNASDAQ:RDHLRedhill Biopharma Ltd
05/09/202413h00PR Newswire (US)RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:RDHLRedhill Biopharma Ltd
03/09/202413h00PR Newswire (US)New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 MortalityNASDAQ:RDHLRedhill Biopharma Ltd
29/08/202413h00PR Newswire (US)RedHill Biopharma Announces First Half 2024 Business HighlightsNASDAQ:RDHLRedhill Biopharma Ltd
26/08/202413h00PR Newswire (US)RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, NeuroblastomaNASDAQ:RDHLRedhill Biopharma Ltd
21/08/202413h00PR Newswire (US)Talicia® Launched in the United Arab EmiratesNASDAQ:RDHLRedhill Biopharma Ltd
20/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RDHLRedhill Biopharma Ltd
19/08/202413h00PR Newswire (US)RedHill Announces Positive Obesity and Diabetes Results with OpaganibNASDAQ:RDHLRedhill Biopharma Ltd
16/08/202413h00PR Newswire (US)RedHill Biopharma Announces Plan to Implement ADS Ratio ChangeNASDAQ:RDHLRedhill Biopharma Ltd
13/08/202419h37Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RDHLRedhill Biopharma Ltd
09/08/202413h01Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:RDHLRedhill Biopharma Ltd
07/08/202422h43Edgar (US Regulatory)Form SCHEDULE 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:RDHLRedhill Biopharma Ltd
01/08/202413h00PR Newswire (US)Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's DiseaseNASDAQ:RDHLRedhill Biopharma Ltd
22/07/202413h00PR Newswire (US)RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® LienNASDAQ:RDHLRedhill Biopharma Ltd
09/07/202414h00PR Newswire (US)RedHill Biopharma Terminates License Agreement for Aemcolo®NASDAQ:RDHLRedhill Biopharma Ltd
20/06/202413h23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RDHLRedhill Biopharma Ltd
06/05/202413h00PR Newswire (US)RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035NASDAQ:RDHLRedhill Biopharma Ltd
 Showing the most relevant articles for your search:NASDAQ:RDHL

Dernières Valeurs Consultées

EU
CAP
Capgemini
NASDAQ
MSFT
Microsoft
COIN
DOGEUSD
Dogecoin
USI
USTECH100
US Tech 100
EU
ORA
Orange
NASDAQ
NVDA
NVIDIA
FTSE
UKX
FTSE 100
COIN
ADAUSD
Cardano
COIN
XRPUSD
Ripple
NYSE
MRK
Merck
EU
PX4
SBF 120
NYSE
NKE
Nike
EU
BNP
BNP Paribas
EU
LR
Legrand
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces